Navigation Links
Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
Date:12/14/2007

eform Act of 1995

Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research; product development including, but not limited to, the successful development of JUVISTA(R) (Human TGFbeta3) and GA-GCB (velaglucerase alfa); manufacturing and commercialization including, but not limited to, the launch and establishment in the market of VYVANSE(TM)(lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder ("ADHD")); the impact of competitive products including, but not limited to, the impact of those on Shire's ADHD franchise; patents including, but not limited to, legal challenges relating to Shire's ADHD franchise; government regulation and approval including, but not limited to, the expected product approval date of INTUNIV(TM) (guanfacine extended release) (ADHD); Shire's ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire plc's filings with the Securities and Exchange Commission, particularly Shire plc's Annual Report on Form 10-K for the year ended December 31, 2006.

(1) Source: Rewers, Gastroenterology vol128, 2005


'/>"/>
SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. ATS Medical Expands Open Pivot Heart Valve Offerings
9. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
10. BioLife Solutions Expands Scientific Advisory Board
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... Scientists at the Center for Learning and ... the California -based biopharmaceutical company Magceutics, ... for reversing memory decline in mice with Alzheimer,s Disease. ... improvement in advanced stage AD mice. The study is ... decline for advanced stage AD mice, and is also ...
(Date:5/16/2013)... Toronto, Canada (PRWEB) May 16, 2013 ... years and costs over one billion dollars. Despite this ... market. With stakes this high, is your clinical trial ... and deliver the best outcomes? , Dr. Frederic Sax, ... Quintiles, will discuss the use of data, information and ...
(Date:5/16/2013)... 16, 2013 Reportlinker.com announces ... is available in its catalogue: ... for Acute Coronary Syndromes - APAC ... http://www.reportlinker.com/p01182969/MediPoint-Diagnostic-Cardiac-Biomarkers-for-Acute-Coronary-Syndromes---APAC-Analysis-and-Market-Forecasts.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic MediPoint: ... Syndromes - APAC Analysis and Market ...
(Date:5/16/2013)... DNA Genotek, a leading provider of products for ... program in conjunction with the African Society of Human Genetics ... reduce the cost of DNA collection for locally ... and Health in Africa (H3 Africa) Initiative and to facilitate ... the AfSHG is to build the capacity of ...
Breaking Biology Technology:Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3Optimizing Clinical Trials Outcomes through Computer Assisted Design, New Life Science Webinar Hosted by Xtalks 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 2MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 3MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 4MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 5MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 6MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 7MediPoint: Diagnostic Cardiac Biomarkers for Acute Coronary Syndromes - APAC Analysis and Market Forecasts 8DNA Genotek Inc. Announces Spit for Africa Program 2DNA Genotek Inc. Announces Spit for Africa Program 3
... Selexis SA, a Swiss-based biotechnology company with technologies ... yield and stable mammalian cell lines for therapeutic ... from the Company will be participating in the ... held Jun 27-30 in Washington, D.C. at the ...
... of a new quasiparticle called the "hybrid plasmon ... photonic circuits and optical computing for the 21st ... (DOE),s Lawrence Berkeley National Laboratory (Berkeley Lab) have ... generation on-chip optical communication systems. "We ...
... Inc. (Nasdaq: AMLN ) will be presenting at the ... 2011, at 12:20 p.m. ET / 9:20 a.m. PT ... Life Sciences Conference on Wednesday, June 8, 2011, at 10:00 a.m. ... New York.  Daniel M. Bradbury, president and chief executive officer ...
Cached Biology Technology:Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC 2Nanoscale waveguide for future photonics 2Nanoscale waveguide for future photonics 3Nanoscale waveguide for future photonics 4
(Date:5/18/2013)... Research presented at Digestive Disease Week (DDW) ... diet and lifestyle. , Individuals suffering from ... strength, fatigue and poor quality of life. These ... remission. A randomized, double blind, placebo-controlled study found ... corresponded to significant relief of these symptoms. ...
(Date:5/17/2013)... MD (May 18, 2013) The AGA Research Foundation ... into the relationship between the gut microbiota, one of ... and disease. , The AGA Research Awards Panel ... from Massachusetts General Hospital and Harvard Medical School, Boston, ... recipient. Dr. Chan will receive $25,000 of funding, commencing ...
(Date:5/17/2013)... State University of New Jersey, and City University of ... Visikol TM that effectively clears organisms to be ... of chloral hydrate, which is one of the few ... regulated by the Drug Enforcement Administration (DEA) due to ... clearing agents, are vital for viewing organisms under a ...
Breaking Biology News(10 mins):Research examines new methods for managing digestive health 2Research examines new methods for managing digestive health 3New gut microbiome research to explore red meat -- colorectal cancer pathway 2New formula invented for microscope viewing, substitutes for federally controlled drug 2New formula invented for microscope viewing, substitutes for federally controlled drug 3
... 4, 2011 Venture capital (VC) funding in the ... and Medical Device industries, recovered in terms of dollar ... a new PwC US report, "A Case for Cautious ... PricewaterhouseCoopers LLP/National Venture Capital Association MoneyTree™ Report, based on ...
... ecology, the removal or addition of a predator to an ... species. For the first time, scientists have observed the same ... that decimated ocean life 360 million years ago. What ... according to a paper published today in Proceedings of ...
... Durham, NC Most of us wouldn,t consider slow-moving snails ... distant past, snail metabolism sped up, says a new study ... "Many of the marine snails we recognize today such ... twice as much energy to survive as their ancestors did," ...
Cached Biology News:Life Sciences Venture Capital Investment Level Rebounds in Q1 2011 but Deal Volume Declines, According to the MoneyTree Report 2Life Sciences Venture Capital Investment Level Rebounds in Q1 2011 but Deal Volume Declines, According to the MoneyTree Report 3Life Sciences Venture Capital Investment Level Rebounds in Q1 2011 but Deal Volume Declines, According to the MoneyTree Report 4The winners of mass extinction: With predators gone, prey thrives 2The winners of mass extinction: With predators gone, prey thrives 3Marine snails get a metabolism boost 2
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Recombinant Human Erythropoietin (Tissue Culture Grade)...
Acrylamide PAGE 40% Solution, 1 l. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Gel Casting Chemicals....
Recombinant Mouse IL-23, CF...
Biology Products: